| 1 | iii | 16,262 |
| 2 | iib | 734 |
| 3 | i-ii | 521 |
| 4 | iiib | 411 |
| 5 | i/ii | 402 |
| 6 | iii-iv | 350 |
| 7 | iii/iv | 326 |
| 8 | iiia | 300 |
| 9 | ii/iii | 289 |
| 10 | i-iii | 281 |
| 11 | ii-iv | 256 |
| 12 | ii-iii | 243 |
| 13 | iiib/iv | 91 |
| 14 | i-iv | 88 |
| 15 | 1-98 | 64 |
| 16 | iiic | 63 |
| 17 | iii-v | 47 |
| 18 | iv-v | 35 |
| 19 | iiib-iv | 31 |
| 20 | ib2 | 22 |
| 21 | iib/iii | 22 |
| 22 | i-iiia | 20 |
| 23 | ia1 | 20 |
| 24 | 2b/3 | 19 |
| 25 | i/iia | 19 |
| 26 | iib-iv | 17 |
| 27 | ia2 | 16 |
| 28 | ii-v | 15 |
| 29 | i+ii | 14 |
| 30 | iiia-n2 | 14 |
| 31 | 0-iii | 13 |
| 32 | ≥ii | 13 |
| 33 | medac | 12 |
| 34 | ii+ | 11 |
| 35 | iv/v | 11 |
| 36 | i-iia | 10 |
| 37 | ≥iii | 10 |
| 38 | 3016 | 9 |
| 39 | ic-iv | 9 |
| 40 | iiiβ-tubulin | 9 |
| 41 | iib-iva | 8 |
| 42 | i-h | 7 |
| 43 | i/ii/iii/iv | 7 |
| 44 | ib/ii | 7 |
| 45 | iiia/b | 7 |
| 46 | 5t | 6 |
| 47 | 8794 | 6 |
| 48 | i-iiib | 6 |
| 49 | ib-iiia | 6 |
| 50 | 0-i | 5 |
| 51 | 0-ii | 5 |
| 52 | 3a+ | 5 |
| 53 | ib-iia | 5 |
| 54 | ib/iia | 5 |
| 55 | ib2-iva | 5 |
| 56 | ii-iiib | 5 |
| 57 | ii/iiia | 5 |
| 58 | iib-iiib | 5 |
| 59 | iib-iiic | 5 |
| 60 | iiia/iiib | 5 |
| 61 | 3-vi | 4 |
| 62 | 3a/3b | 4 |
| 63 | 3b/4 | 4 |
| 64 | 5-ii | 4 |
| 65 | bev/ifn | 4 |
| 66 | ex-l | 4 |
| 67 | i-iib | 4 |
| 68 | i-viii | 4 |
| 69 | ia-iia | 4 |
| 70 | ia/ib | 4 |
| 71 | ib-iiib | 4 |
| 72 | iia/b | 4 |
| 73 | iii-iva | 4 |
| 74 | iii-ivb | 4 |
| 75 | iiia-iiib | 4 |
| 76 | iiic/iv | 4 |
| 77 | iv/iv | 4 |
| 78 | pentron | 4 |
| 79 | prospective/retrospective | 4 |
| 80 | pt1a | 4 |
| 81 | v+iii | 4 |
| 82 | ≤ii | 4 |
| 83 | ≥2/4 | 4 |
| 84 | 0-p | 3 |
| 85 | 0/i | 3 |
| 86 | 1/2b | 3 |
| 87 | 2b-3 | 3 |
| 88 | 4t | 3 |
| 89 | caldilineae | 3 |
| 90 | i-associated | 3 |
| 91 | ib-iib | 3 |
| 92 | ib-iii | 3 |
| 93 | ib2-iib | 3 |
| 94 | ii-prospective | 3 |
| 95 | ii/1 | 3 |
| 96 | iii/iva | 3 |
| 97 | noradrenalina | 3 |
| 98 | tock | 3 |
| 99 | vert | 3 |
| 100 | vhrd | 3 |
| 101 | 0-iib | 2 |
| 102 | 0-iv | 2 |
| 103 | 1-hypertension | 2 |
| 104 | 1-methoxy-2-propanol | 2 |
| 105 | 1/1b | 2 |
| 106 | 1/condyloma | 2 |
| 107 | 2b-4 | 2 |
| 108 | 3/cis | 2 |
| 109 | 45±14 | 2 |
| 110 | 90aa | 2 |
| 111 | a-cll | 2 |
| 112 | aml15 | 2 |
| 113 | angiotensin-system | 2 |
| 114 | attom | 2 |
| 115 | b-231 | 2 |
| 116 | b-rt | 2 |
| 117 | c8h18n3o2 | 2 |
| 118 | cheea | 2 |
| 119 | co4a | 2 |
| 120 | colt | 2 |
| 121 | cr-2000 | 2 |
| 122 | criteria-non-matched | 2 |
| 123 | eccds | 2 |
| 124 | f2-f4 | 2 |
| 125 | hadv50 | 2 |
| 126 | hrh | 2 |
| 127 | i-ii-iii | 2 |
| 128 | i/ii-studies | 2 |
| 129 | ib-iva | 2 |
| 130 | ie/iie | 2 |
| 131 | ii-defined | 2 |
| 132 | ii-expressing | 2 |
| 133 | ii-trial | 2 |
| 134 | ii/iib | 2 |
| 135 | ii=22 | 2 |
| 136 | iia-c | 2 |
| 137 | iia-iiib | 2 |
| 138 | iia2 | 2 |
| 139 | iii+ | 2 |
| 140 | iii-n2 | 2 |
| 141 | iii/ic | 2 |
| 142 | iiib+iv | 2 |
| 143 | iiib-c | 2 |
| 144 | iiic-iv | 2 |
| 145 | ilate/ii | 2 |
| 146 | individual-randomized | 2 |
| 147 | iv-acs | 2 |
| 148 | ktedonobacteria | 2 |
| 149 | marval | 2 |
| 150 | mds-003 | 2 |
| 151 | medians-x-time | 2 |
| 152 | preconcept | 2 |
| 153 | pt2n0m0 | 2 |
| 154 | pta-pt1 | 2 |
| 155 | shifter | 2 |
| 156 | stonees | 2 |
| 157 | tmrt | 2 |
| 158 | toscar | 2 |
| 159 | v/vi | 2 |
| 160 | valga | 2 |
| 161 | wave-2 | 2 |
| 162 | +r | 1 |
| 163 | 0-0-2-0 | 1 |
| 164 | 0-iiia | 1 |
| 165 | 0/1/2/3 | 1 |
| 166 | 1-2b | 1 |
| 167 | 1-therapeutic | 1 |
| 168 | 1.0-2.75 | 1 |
| 169 | 1.2+ | 1 |
| 170 | 1.24-hour | 1 |
| 171 | 1.4/4 | 1 |
| 172 | 1/pharmacodynamic | 1 |
| 173 | 10,283 | 1 |
| 174 | 10.0-29.8 | 1 |
| 175 | 11,328 | 1 |
| 176 | 11871 | 1 |
| 177 | 14203 | 1 |
| 178 | 1=633 | 1 |
| 179 | 1a-d | 1 |
| 180 | 1a/2a | 1 |
| 181 | 1b-2 | 1 |
| 182 | 1b-2a | 1 |
| 183 | 1b/2 | 1 |
| 184 | 1b/2a | 1 |
| 185 | 1b/2b/3 | 1 |
| 186 | 1i+ | 1 |
| 187 | 2-0-0 | 1 |
| 188 | 2-0-1-1 | 1 |
| 189 | 2-therapeutic | 1 |
| 190 | 2.1.1 | 1 |
| 191 | 2.4+/-0.8 | 1 |
| 192 | 2/2b | 1 |
| 193 | 2/3/4 | 1 |
| 194 | 2/3/invasion | 1 |
| 195 | 2000~~ | 1 |
| 196 | 2=710 | 1 |
| 197 | 2a-3 | 1 |
| 198 | 2∼4 | 1 |
| 199 | 3-greater | 1 |
| 200 | 3-refined | 1 |
| 201 | 3-vmh | 1 |
| 202 | 3.25-9.0 | 1 |
| 203 | 3.3-3.4 | 1 |
| 204 | 3/carcinoma | 1 |
| 205 | 3/machado-joseph | 1 |
| 206 | 33:38-44 | 1 |
| 207 | 38.5-48.5 | 1 |
| 208 | 3=576 | 1 |
| 209 | 3b-5 | 1 |
| 210 | 4-5-6 | 1 |
| 211 | 41833 | 1 |
| 212 | 43,551 | 1 |
| 213 | 45-second | 1 |
| 214 | 4=403 | 1 |
| 215 | 5-knockout | 1 |
| 216 | 5/left | 1 |
| 217 | 55/265 | 1 |
| 218 | 5cb | 1 |
| 219 | 65-74yr | 1 |
| 220 | 8/left | 1 |
| 221 | a-hsfs | 1 |
| 222 | a-progressive | 1 |
| 223 | a-valve | 1 |
| 224 | a=1325.8+/-1500.3 | 1 |
| 225 | a=large | 1 |
| 226 | aminoethylphosphonate | 1 |
| 227 | anaerolinea | 1 |
| 228 | antiepileptics/barbiturates | 1 |
| 229 | approach.one | 1 |
| 230 | archiacanthocephala | 1 |
| 231 | aspirin-assigned | 1 |
| 232 | b.o.o | 1 |
| 233 | b27+ | 1 |
| 234 | b7-c10 | 1 |
| 235 | bas1 | 1 |
| 236 | c-a6 | 1 |
| 237 | class-matched | 1 |
| 238 | co16 | 1 |
| 239 | contrast-calculated | 1 |
| 240 | criteria-matched | 1 |
| 241 | cyanidiophyceae | 1 |
| 242 | dehydrogenase-bright-treated | 1 |
| 243 | e2993 | 1 |
| 244 | ends-products | 1 |
| 245 | eyetoy™ | 1 |
| 246 | fluoride-trifluoroethylene | 1 |
| 247 | glucose-stimulated- | 1 |
| 248 | gradei-iii | 1 |
| 249 | hyperodapedon | 1 |
| 250 | i+ii+iii | 1 |
| 251 | i+prim-o-glucosylcimifugin | 1 |
| 252 | i-binding | 1 |
| 253 | i-ii-iiicn0 | 1 |
| 254 | i-ii/iv | 1 |
| 255 | i-iva | 1 |
| 256 | i-outreach | 1 |
| 257 | i-study | 1 |
| 258 | i/ii-cinderella-trial | 1 |
| 259 | i/iib | 1 |
| 260 | i=19 | 1 |
| 261 | ia-1 | 1 |
| 262 | ia-ib | 1 |
| 263 | ia-ib-iia-iib | 1 |
| 264 | ia-ii | 1 |
| 265 | ia/iib | 1 |
| 266 | ia1-iib | 1 |
| 267 | ib-ii | 1 |
| 268 | ib-pt3n1 | 1 |
| 269 | ib1-iia | 1 |
| 270 | ib1-iv | 1 |
| 271 | ib1-iva | 1 |
| 272 | ib2-iiib | 1 |
| 273 | icg1/2 | 1 |
| 274 | ii-109 | 1 |
| 275 | ii-cleopatra-study | 1 |
| 276 | ii-detoxifying | 1 |
| 277 | ii-gold | 1 |
| 278 | ii-iva | 1 |
| 279 | ii-targeted | 1 |
| 280 | ii-typed | 1 |
| 281 | ii/266 | 1 |
| 282 | ii/iiiab | 1 |
| 283 | iia-iib | 1 |
| 284 | iia-iv | 1 |
| 285 | iia-study | 1 |
| 286 | iialpha-amplified | 1 |
| 287 | iib-iic | 1 |
| 288 | iib-study | 1 |
| 289 | iib/c-iii | 1 |
| 290 | iib/iii-n1 | 1 |
| 291 | iic-iv | 1 |
| 292 | iii+v | 1 |
| 293 | iii-59 | 1 |
| 294 | iii-based | 1 |
| 295 | iii-controlled | 1 |
| 296 | iii-ivm0 | 1 |
| 297 | iii-sandblasting | 1 |
| 298 | iii-trials | 1 |
| 299 | iii-viii | 1 |
| 300 | iii/aha | 1 |
| 301 | iii/america | 1 |
| 302 | iii=28 | 1 |
| 303 | iiia-b | 1 |
| 304 | iiia-iv | 1 |
| 305 | iiia/b/iv | 1 |
| 306 | iiian2 | 1 |
| 307 | iiib/inflammatory | 1 |
| 308 | iiibwet | 1 |
| 309 | iiisa | 1 |
| 310 | iii–iv | 1 |
| 311 | ili-iv | 1 |
| 312 | ill-recommended | 1 |
| 313 | immmunoadsorbent | 1 |
| 314 | indices-mepi | 1 |
| 315 | iorii | 1 |
| 316 | iv+ | 1 |
| 317 | iv-i | 1 |
| 318 | iv/cd4 | 1 |
| 319 | iv/unstaged | 1 |
| 320 | iv/vi | 1 |
| 321 | iv=32 | 1 |
| 322 | iva-b | 1 |
| 323 | iva/b | 1 |
| 324 | iv‒v | 1 |
| 325 | i‒iii | 1 |
| 326 | la3bwo9 | 1 |
| 327 | melter | 1 |
| 328 | moln1 | 1 |
| 329 | n=40/46 | 1 |
| 330 | na3ni2fe | 1 |
| 331 | nyha=4 | 1 |
| 332 | paleotemperature | 1 |
| 333 | ph+cml | 1 |
| 334 | polyphenism | 1 |
| 335 | post-integration | 1 |
| 336 | pounder | 1 |
| 337 | prdx-2 | 1 |
| 338 | progesterone-dependent | 1 |
| 339 | pt1-3n2m0 | 1 |
| 340 | pt3an0m0 | 1 |
| 341 | ptnmi | 1 |
| 342 | ptnmii | 1 |
| 343 | ptnmiii | 1 |
| 344 | randomized/nonrandomized | 1 |
| 345 | rates.this | 1 |
| 346 | recondition | 1 |
| 347 | report-3 | 1 |
| 348 | rerg | 1 |
| 349 | s3+s4 | 1 |
| 350 | sc-ovcar-3 | 1 |
| 351 | seco-casbane | 1 |
| 352 | self-resolution | 1 |
| 353 | shifters | 1 |
| 354 | sitong | 1 |
| 355 | sphingobacteriia | 1 |
| 356 | t1-3n0-2 | 1 |
| 357 | t1-4n0-1 | 1 |
| 358 | t1-t2n1 | 1 |
| 359 | t1/t2nxm0 | 1 |
| 360 | t1b-2b | 1 |
| 361 | t1b-t2b | 1 |
| 362 | t1b-t4 | 1 |
| 363 | t1m0 | 1 |
| 364 | t2-4n0-1m0 | 1 |
| 365 | t2-4nzero-1mzero | 1 |
| 366 | t2-t4ac | 1 |
| 367 | t2n2 | 1 |
| 368 | t3/c | 1 |
| 369 | t3a-t3b | 1 |
| 370 | t3b-c | 1 |
| 371 | t3n0-1m0gx | 1 |
| 372 | thermomicrobia | 1 |
| 373 | txn2-3m0 | 1 |
| 374 | ut1a | 1 |
| 375 | v-iv | 1 |
| 376 | wallemiomycetes | 1 |
| 377 | yun-xian | 1 |
| 378 | zona-pellucida | 1 |
| 379 | β-mote2 | 1 |
| 380 | βeta- | 1 |
| 381 | ι-ii | 1 |
| 382 | €845 | 1 |
| 383 | ⅲ/ⅳ | 1 |
| 384 | ≤iii | 1 |
| 385 | ≤t2 | 1 |
| 386 | ≥3a | 1 |
| 387 | ≥a1 | 1 |
| 388 | ≥i | 1 |
| 389 | ≥t2c | 1 |
| 390 | ≥t3a | 1 |
| 391 | ≧1 | 1 |
| 1 | +r | 1 |
| 2 | 0-0-2-0 | 1 |
| 3 | 0-i | 5 |
| 4 | 0-ii | 5 |
| 5 | 0-iib | 2 |
| 6 | 0-iii | 13 |
| 7 | 0-iiia | 1 |
| 8 | 0-iv | 2 |
| 9 | 0-p | 3 |
| 10 | 0/1/2/3 | 1 |
| 11 | 0/i | 3 |
| 12 | 1-2b | 1 |
| 13 | 1-98 | 64 |
| 14 | 1-hypertension | 2 |
| 15 | 1-methoxy-2-propanol | 2 |
| 16 | 1-therapeutic | 1 |
| 17 | 1.0-2.75 | 1 |
| 18 | 1.2+ | 1 |
| 19 | 1.24-hour | 1 |
| 20 | 1.4/4 | 1 |
| 21 | 1/1b | 2 |
| 22 | 1/2b | 3 |
| 23 | 1/condyloma | 2 |
| 24 | 1/pharmacodynamic | 1 |
| 25 | 10,283 | 1 |
| 26 | 10.0-29.8 | 1 |
| 27 | 11,328 | 1 |
| 28 | 11871 | 1 |
| 29 | 14203 | 1 |
| 30 | 1=633 | 1 |
| 31 | 1a-d | 1 |
| 32 | 1a/2a | 1 |
| 33 | 1b-2 | 1 |
| 34 | 1b-2a | 1 |
| 35 | 1b/2 | 1 |
| 36 | 1b/2a | 1 |
| 37 | 1b/2b/3 | 1 |
| 38 | 1i+ | 1 |
| 39 | 2-0-0 | 1 |
| 40 | 2-0-1-1 | 1 |
| 41 | 2-therapeutic | 1 |
| 42 | 2.1.1 | 1 |
| 43 | 2.4+/-0.8 | 1 |
| 44 | 2/2b | 1 |
| 45 | 2/3/4 | 1 |
| 46 | 2/3/invasion | 1 |
| 47 | 2000~~ | 1 |
| 48 | 2=710 | 1 |
| 49 | 2a-3 | 1 |
| 50 | 2b-3 | 3 |
| 51 | 2b-4 | 2 |
| 52 | 2b/3 | 19 |
| 53 | 2∼4 | 1 |
| 54 | 3-greater | 1 |
| 55 | 3-refined | 1 |
| 56 | 3-vi | 4 |
| 57 | 3-vmh | 1 |
| 58 | 3.25-9.0 | 1 |
| 59 | 3.3-3.4 | 1 |
| 60 | 3/carcinoma | 1 |
| 61 | 3/cis | 2 |
| 62 | 3/machado-joseph | 1 |
| 63 | 3016 | 9 |
| 64 | 33:38-44 | 1 |
| 65 | 38.5-48.5 | 1 |
| 66 | 3=576 | 1 |
| 67 | 3a+ | 5 |
| 68 | 3a/3b | 4 |
| 69 | 3b-5 | 1 |
| 70 | 3b/4 | 4 |
| 71 | 4-5-6 | 1 |
| 72 | 41833 | 1 |
| 73 | 43,551 | 1 |
| 74 | 45-second | 1 |
| 75 | 45±14 | 2 |
| 76 | 4=403 | 1 |
| 77 | 4t | 3 |
| 78 | 5-ii | 4 |
| 79 | 5-knockout | 1 |
| 80 | 5/left | 1 |
| 81 | 55/265 | 1 |
| 82 | 5cb | 1 |
| 83 | 5t | 6 |
| 84 | 65-74yr | 1 |
| 85 | 8/left | 1 |
| 86 | 8794 | 6 |
| 87 | 90aa | 2 |
| 88 | a-cll | 2 |
| 89 | a-hsfs | 1 |
| 90 | a-progressive | 1 |
| 91 | a-valve | 1 |
| 92 | a=1325.8+/-1500.3 | 1 |
| 93 | a=large | 1 |
| 94 | aminoethylphosphonate | 1 |
| 95 | aml15 | 2 |
| 96 | anaerolinea | 1 |
| 97 | angiotensin-system | 2 |
| 98 | antiepileptics/barbiturates | 1 |
| 99 | approach.one | 1 |
| 100 | archiacanthocephala | 1 |
| 101 | aspirin-assigned | 1 |
| 102 | attom | 2 |
| 103 | b-231 | 2 |
| 104 | b-rt | 2 |
| 105 | b.o.o | 1 |
| 106 | b27+ | 1 |
| 107 | b7-c10 | 1 |
| 108 | bas1 | 1 |
| 109 | bev/ifn | 4 |
| 110 | c-a6 | 1 |
| 111 | c8h18n3o2 | 2 |
| 112 | caldilineae | 3 |
| 113 | cheea | 2 |
| 114 | class-matched | 1 |
| 115 | co16 | 1 |
| 116 | co4a | 2 |
| 117 | colt | 2 |
| 118 | contrast-calculated | 1 |
| 119 | cr-2000 | 2 |
| 120 | criteria-matched | 1 |
| 121 | criteria-non-matched | 2 |
| 122 | cyanidiophyceae | 1 |
| 123 | dehydrogenase-bright-treated | 1 |
| 124 | e2993 | 1 |
| 125 | eccds | 2 |
| 126 | ends-products | 1 |
| 127 | ex-l | 4 |
| 128 | eyetoy™ | 1 |
| 129 | f2-f4 | 2 |
| 130 | fluoride-trifluoroethylene | 1 |
| 131 | glucose-stimulated- | 1 |
| 132 | gradei-iii | 1 |
| 133 | hadv50 | 2 |
| 134 | hrh | 2 |
| 135 | hyperodapedon | 1 |
| 136 | i+ii | 14 |
| 137 | i+ii+iii | 1 |
| 138 | i+prim-o-glucosylcimifugin | 1 |
| 139 | i-associated | 3 |
| 140 | i-binding | 1 |
| 141 | i-h | 7 |
| 142 | i-ii | 521 |
| 143 | i-ii-iii | 2 |
| 144 | i-ii-iiicn0 | 1 |
| 145 | i-ii/iv | 1 |
| 146 | i-iia | 10 |
| 147 | i-iib | 4 |
| 148 | i-iii | 281 |
| 149 | i-iiia | 20 |
| 150 | i-iiib | 6 |
| 151 | i-iv | 88 |
| 152 | i-iva | 1 |
| 153 | i-outreach | 1 |
| 154 | i-study | 1 |
| 155 | i-viii | 4 |
| 156 | i/ii | 402 |
| 157 | i/ii-cinderella-trial | 1 |
| 158 | i/ii-studies | 2 |
| 159 | i/ii/iii/iv | 7 |
| 160 | i/iia | 19 |
| 161 | i/iib | 1 |
| 162 | i=19 | 1 |
| 163 | ia-1 | 1 |
| 164 | ia-ib | 1 |
| 165 | ia-ib-iia-iib | 1 |
| 166 | ia-ii | 1 |
| 167 | ia-iia | 4 |
| 168 | ia/ib | 4 |
| 169 | ia/iib | 1 |
| 170 | ia1 | 20 |
| 171 | ia1-iib | 1 |
| 172 | ia2 | 16 |
| 173 | ib-ii | 1 |
| 174 | ib-iia | 5 |
| 175 | ib-iib | 3 |
| 176 | ib-iii | 3 |
| 177 | ib-iiia | 6 |
| 178 | ib-iiib | 4 |
| 179 | ib-iva | 2 |
| 180 | ib-pt3n1 | 1 |
| 181 | ib/ii | 7 |
| 182 | ib/iia | 5 |
| 183 | ib1-iia | 1 |
| 184 | ib1-iv | 1 |
| 185 | ib1-iva | 1 |
| 186 | ib2 | 22 |
| 187 | ib2-iib | 3 |
| 188 | ib2-iiib | 1 |
| 189 | ib2-iva | 5 |
| 190 | ic-iv | 9 |
| 191 | icg1/2 | 1 |
| 192 | ie/iie | 2 |
| 193 | ii+ | 11 |
| 194 | ii-109 | 1 |
| 195 | ii-cleopatra-study | 1 |
| 196 | ii-defined | 2 |
| 197 | ii-detoxifying | 1 |
| 198 | ii-expressing | 2 |
| 199 | ii-gold | 1 |
| 200 | ii-iii | 243 |
| 201 | ii-iiib | 5 |
| 202 | ii-iv | 256 |
| 203 | ii-iva | 1 |
| 204 | ii-prospective | 3 |
| 205 | ii-targeted | 1 |
| 206 | ii-trial | 2 |
| 207 | ii-typed | 1 |
| 208 | ii-v | 15 |
| 209 | ii/1 | 3 |
| 210 | ii/266 | 1 |
| 211 | ii/iib | 2 |
| 212 | ii/iii | 289 |
| 213 | ii/iiia | 5 |
| 214 | ii/iiiab | 1 |
| 215 | ii=22 | 2 |
| 216 | iia-c | 2 |
| 217 | iia-iib | 1 |
| 218 | iia-iiib | 2 |
| 219 | iia-iv | 1 |
| 220 | iia-study | 1 |
| 221 | iia/b | 4 |
| 222 | iia2 | 2 |
| 223 | iialpha-amplified | 1 |
| 224 | iib | 734 |
| 225 | iib-iic | 1 |
| 226 | iib-iiib | 5 |
| 227 | iib-iiic | 5 |
| 228 | iib-iv | 17 |
| 229 | iib-iva | 8 |
| 230 | iib-study | 1 |
| 231 | iib/c-iii | 1 |
| 232 | iib/iii | 22 |
| 233 | iib/iii-n1 | 1 |
| 234 | iic-iv | 1 |
| 235 | iii | 16,262 |
| 236 | iii+ | 2 |
| 237 | iii+v | 1 |
| 238 | iii-59 | 1 |
| 239 | iii-based | 1 |
| 240 | iii-controlled | 1 |
| 241 | iii-iv | 350 |
| 242 | iii-iva | 4 |
| 243 | iii-ivb | 4 |
| 244 | iii-ivm0 | 1 |
| 245 | iii-n2 | 2 |
| 246 | iii-sandblasting | 1 |
| 247 | iii-trials | 1 |
| 248 | iii-v | 47 |
| 249 | iii-viii | 1 |
| 250 | iii/aha | 1 |
| 251 | iii/america | 1 |
| 252 | iii/ic | 2 |
| 253 | iii/iv | 326 |
| 254 | iii/iva | 3 |
| 255 | iii=28 | 1 |
| 256 | iiia | 300 |
| 257 | iiia-b | 1 |
| 258 | iiia-iiib | 4 |
| 259 | iiia-iv | 1 |
| 260 | iiia-n2 | 14 |
| 261 | iiia/b | 7 |
| 262 | iiia/b/iv | 1 |
| 263 | iiia/iiib | 5 |
| 264 | iiian2 | 1 |
| 265 | iiib | 411 |
| 266 | iiib+iv | 2 |
| 267 | iiib-c | 2 |
| 268 | iiib-iv | 31 |
| 269 | iiib/inflammatory | 1 |
| 270 | iiib/iv | 91 |
| 271 | iiibwet | 1 |
| 272 | iiic | 63 |
| 273 | iiic-iv | 2 |
| 274 | iiic/iv | 4 |
| 275 | iiisa | 1 |
| 276 | iiiβ-tubulin | 9 |
| 277 | iii–iv | 1 |
| 278 | ilate/ii | 2 |
| 279 | ili-iv | 1 |
| 280 | ill-recommended | 1 |
| 281 | immmunoadsorbent | 1 |
| 282 | indices-mepi | 1 |
| 283 | individual-randomized | 2 |
| 284 | iorii | 1 |
| 285 | iv+ | 1 |
| 286 | iv-acs | 2 |
| 287 | iv-i | 1 |
| 288 | iv-v | 35 |
| 289 | iv/cd4 | 1 |
| 290 | iv/iv | 4 |
| 291 | iv/unstaged | 1 |
| 292 | iv/v | 11 |
| 293 | iv/vi | 1 |
| 294 | iv=32 | 1 |
| 295 | iva-b | 1 |
| 296 | iva/b | 1 |
| 297 | iv‒v | 1 |
| 298 | i‒iii | 1 |
| 299 | ktedonobacteria | 2 |
| 300 | la3bwo9 | 1 |
| 301 | marval | 2 |
| 302 | mds-003 | 2 |
| 303 | medac | 12 |
| 304 | medians-x-time | 2 |
| 305 | melter | 1 |
| 306 | moln1 | 1 |
| 307 | n=40/46 | 1 |
| 308 | na3ni2fe | 1 |
| 309 | noradrenalina | 3 |
| 310 | nyha=4 | 1 |
| 311 | paleotemperature | 1 |
| 312 | pentron | 4 |
| 313 | ph+cml | 1 |
| 314 | polyphenism | 1 |
| 315 | post-integration | 1 |
| 316 | pounder | 1 |
| 317 | prdx-2 | 1 |
| 318 | preconcept | 2 |
| 319 | progesterone-dependent | 1 |
| 320 | prospective/retrospective | 4 |
| 321 | pt1-3n2m0 | 1 |
| 322 | pt1a | 4 |
| 323 | pt2n0m0 | 2 |
| 324 | pt3an0m0 | 1 |
| 325 | pta-pt1 | 2 |
| 326 | ptnmi | 1 |
| 327 | ptnmii | 1 |
| 328 | ptnmiii | 1 |
| 329 | randomized/nonrandomized | 1 |
| 330 | rates.this | 1 |
| 331 | recondition | 1 |
| 332 | report-3 | 1 |
| 333 | rerg | 1 |
| 334 | s3+s4 | 1 |
| 335 | sc-ovcar-3 | 1 |
| 336 | seco-casbane | 1 |
| 337 | self-resolution | 1 |
| 338 | shifter | 2 |
| 339 | shifters | 1 |
| 340 | sitong | 1 |
| 341 | sphingobacteriia | 1 |
| 342 | stonees | 2 |
| 343 | t1-3n0-2 | 1 |
| 344 | t1-4n0-1 | 1 |
| 345 | t1-t2n1 | 1 |
| 346 | t1/t2nxm0 | 1 |
| 347 | t1b-2b | 1 |
| 348 | t1b-t2b | 1 |
| 349 | t1b-t4 | 1 |
| 350 | t1m0 | 1 |
| 351 | t2-4n0-1m0 | 1 |
| 352 | t2-4nzero-1mzero | 1 |
| 353 | t2-t4ac | 1 |
| 354 | t2n2 | 1 |
| 355 | t3/c | 1 |
| 356 | t3a-t3b | 1 |
| 357 | t3b-c | 1 |
| 358 | t3n0-1m0gx | 1 |
| 359 | thermomicrobia | 1 |
| 360 | tmrt | 2 |
| 361 | tock | 3 |
| 362 | toscar | 2 |
| 363 | txn2-3m0 | 1 |
| 364 | ut1a | 1 |
| 365 | v+iii | 4 |
| 366 | v-iv | 1 |
| 367 | v/vi | 2 |
| 368 | valga | 2 |
| 369 | vert | 3 |
| 370 | vhrd | 3 |
| 371 | wallemiomycetes | 1 |
| 372 | wave-2 | 2 |
| 373 | yun-xian | 1 |
| 374 | zona-pellucida | 1 |
| 375 | β-mote2 | 1 |
| 376 | βeta- | 1 |
| 377 | ι-ii | 1 |
| 378 | €845 | 1 |
| 379 | ⅲ/ⅳ | 1 |
| 380 | ≤ii | 4 |
| 381 | ≤iii | 1 |
| 382 | ≤t2 | 1 |
| 383 | ≥2/4 | 4 |
| 384 | ≥3a | 1 |
| 385 | ≥a1 | 1 |
| 386 | ≥i | 1 |
| 387 | ≥ii | 13 |
| 388 | ≥iii | 10 |
| 389 | ≥t2c | 1 |
| 390 | ≥t3a | 1 |
| 391 | ≧1 | 1 |
| 1 | 1.2+ | 1 |
| 2 | b27+ | 1 |
| 3 | 3a+ | 5 |
| 4 | 1i+ | 1 |
| 5 | ii+ | 11 |
| 6 | iii+ | 2 |
| 7 | iv+ | 1 |
| 8 | βeta- | 1 |
| 9 | glucose-stimulated- | 1 |
| 10 | 2-0-0 | 1 |
| 11 | 0-0-2-0 | 1 |
| 12 | 3.25-9.0 | 1 |
| 13 | cr-2000 | 2 |
| 14 | 2=710 | 1 |
| 15 | b7-c10 | 1 |
| 16 | hadv50 | 2 |
| 17 | pt2n0m0 | 2 |
| 18 | pt3an0m0 | 1 |
| 19 | t2-4n0-1m0 | 1 |
| 20 | t1m0 | 1 |
| 21 | pt1-3n2m0 | 1 |
| 22 | txn2-3m0 | 1 |
| 23 | iii-ivm0 | 1 |
| 24 | t1/t2nxm0 | 1 |
| 25 | i-ii-iiicn0 | 1 |
| 26 | t1-4n0-1 | 1 |
| 27 | 2-0-1-1 | 1 |
| 28 | ia-1 | 1 |
| 29 | 2.1.1 | 1 |
| 30 | ii/1 | 3 |
| 31 | b-231 | 2 |
| 32 | 43,551 | 1 |
| 33 | 11871 | 1 |
| 34 | ia1 | 20 |
| 35 | ≥a1 | 1 |
| 36 | iib/iii-n1 | 1 |
| 37 | t1-t2n1 | 1 |
| 38 | ib-pt3n1 | 1 |
| 39 | moln1 | 1 |
| 40 | bas1 | 1 |
| 41 | pta-pt1 | 2 |
| 42 | ≧1 | 1 |
| 43 | t1-3n0-2 | 1 |
| 44 | 1b-2 | 1 |
| 45 | wave-2 | 2 |
| 46 | prdx-2 | 1 |
| 47 | icg1/2 | 1 |
| 48 | 1b/2 | 1 |
| 49 | ii=22 | 2 |
| 50 | iv=32 | 1 |
| 51 | ia2 | 16 |
| 52 | iia2 | 2 |
| 53 | ib2 | 22 |
| 54 | β-mote2 | 1 |
| 55 | iiia-n2 | 14 |
| 56 | iii-n2 | 2 |
| 57 | t2n2 | 1 |
| 58 | iiian2 | 1 |
| 59 | c8h18n3o2 | 2 |
| 60 | ≤t2 | 1 |
| 61 | 2a-3 | 1 |
| 62 | 2b-3 | 3 |
| 63 | sc-ovcar-3 | 1 |
| 64 | report-3 | 1 |
| 65 | a=1325.8+/-1500.3 | 1 |
| 66 | 0/1/2/3 | 1 |
| 67 | 2b/3 | 19 |
| 68 | 1b/2b/3 | 1 |
| 69 | mds-003 | 2 |
| 70 | 14203 | 1 |
| 71 | 4=403 | 1 |
| 72 | 1=633 | 1 |
| 73 | 41833 | 1 |
| 74 | 10,283 | 1 |
| 75 | e2993 | 1 |
| 76 | 2b-4 | 2 |
| 77 | 3.3-3.4 | 1 |
| 78 | ≥2/4 | 4 |
| 79 | 2/3/4 | 1 |
| 80 | 1.4/4 | 1 |
| 81 | 3b/4 | 4 |
| 82 | 45±14 | 2 |
| 83 | 33:38-44 | 1 |
| 84 | 8794 | 6 |
| 85 | nyha=4 | 1 |
| 86 | iv/cd4 | 1 |
| 87 | f2-f4 | 2 |
| 88 | s3+s4 | 1 |
| 89 | t1b-t4 | 1 |
| 90 | 2∼4 | 1 |
| 91 | 3b-5 | 1 |
| 92 | 38.5-48.5 | 1 |
| 93 | aml15 | 2 |
| 94 | €845 | 1 |
| 95 | 55/265 | 1 |
| 96 | 1.0-2.75 | 1 |
| 97 | 4-5-6 | 1 |
| 98 | 3016 | 9 |
| 99 | co16 | 1 |
| 100 | n=40/46 | 1 |
| 101 | ii/266 | 1 |
| 102 | 3=576 | 1 |
| 103 | c-a6 | 1 |
| 104 | 2.4+/-0.8 | 1 |
| 105 | 10.0-29.8 | 1 |
| 106 | 11,328 | 1 |
| 107 | iii=28 | 1 |
| 108 | 1-98 | 64 |
| 109 | ii-109 | 1 |
| 110 | i=19 | 1 |
| 111 | iii-59 | 1 |
| 112 | la3bwo9 | 1 |
| 113 | pt1a | 4 |
| 114 | ut1a | 1 |
| 115 | 1b-2a | 1 |
| 116 | 1a/2a | 1 |
| 117 | 1b/2a | 1 |
| 118 | ≥t3a | 1 |
| 119 | ≥3a | 1 |
| 120 | co4a | 2 |
| 121 | 90aa | 2 |
| 122 | iii/america | 1 |
| 123 | zona-pellucida | 1 |
| 124 | cheea | 2 |
| 125 | anaerolinea | 1 |
| 126 | valga | 2 |
| 127 | iii/aha | 1 |
| 128 | thermomicrobia | 1 |
| 129 | ib1-iia | 1 |
| 130 | ia-iia | 4 |
| 131 | ib-iia | 5 |
| 132 | i-iia | 10 |
| 133 | ib/iia | 5 |
| 134 | i/iia | 19 |
| 135 | iiia | 300 |
| 136 | 0-iiia | 1 |
| 137 | ib-iiia | 6 |
| 138 | i-iiia | 20 |
| 139 | ii/iiia | 5 |
| 140 | sphingobacteriia | 1 |
| 141 | ktedonobacteria | 2 |
| 142 | archiacanthocephala | 1 |
| 143 | 1/condyloma | 2 |
| 144 | 3/carcinoma | 1 |
| 145 | noradrenalina | 3 |
| 146 | iiisa | 1 |
| 147 | ib1-iva | 1 |
| 148 | ib2-iva | 5 |
| 149 | ib-iva | 2 |
| 150 | iib-iva | 8 |
| 151 | i-iva | 1 |
| 152 | ii-iva | 1 |
| 153 | iii-iva | 4 |
| 154 | iii/iva | 3 |
| 155 | iiia-b | 1 |
| 156 | iva-b | 1 |
| 157 | iia/b | 4 |
| 158 | iiia/b | 7 |
| 159 | iva/b | 1 |
| 160 | 1/1b | 2 |
| 161 | 1-2b | 1 |
| 162 | t1b-2b | 1 |
| 163 | 1/2b | 3 |
| 164 | 2/2b | 1 |
| 165 | t1b-t2b | 1 |
| 166 | 3a/3b | 4 |
| 167 | t3a-t3b | 1 |
| 168 | ii/iiiab | 1 |
| 169 | 5cb | 1 |
| 170 | ia-ib | 1 |
| 171 | ia/ib | 4 |
| 172 | iib | 734 |
| 173 | 0-iib | 2 |
| 174 | ia1-iib | 1 |
| 175 | ib2-iib | 3 |
| 176 | iia-iib | 1 |
| 177 | ia-ib-iia-iib | 1 |
| 178 | ib-iib | 3 |
| 179 | i-iib | 4 |
| 180 | ia/iib | 1 |
| 181 | i/iib | 1 |
| 182 | ii/iib | 2 |
| 183 | iiib | 411 |
| 184 | ib2-iiib | 1 |
| 185 | iia-iiib | 2 |
| 186 | iiia-iiib | 4 |
| 187 | ib-iiib | 4 |
| 188 | iib-iiib | 5 |
| 189 | i-iiib | 6 |
| 190 | ii-iiib | 5 |
| 191 | iiia/iiib | 5 |
| 192 | iii-ivb | 4 |
| 193 | iia-c | 2 |
| 194 | t3b-c | 1 |
| 195 | iiib-c | 2 |
| 196 | t3/c | 1 |
| 197 | ≥t2c | 1 |
| 198 | t2-t4ac | 1 |
| 199 | medac | 12 |
| 200 | iii/ic | 2 |
| 201 | iib-iic | 1 |
| 202 | iiic | 63 |
| 203 | iib-iiic | 5 |
| 204 | 1/pharmacodynamic | 1 |
| 205 | 1-therapeutic | 1 |
| 206 | 2-therapeutic | 1 |
| 207 | 1a-d | 1 |
| 208 | ill-recommended | 1 |
| 209 | iv/unstaged | 1 |
| 210 | criteria-matched | 1 |
| 211 | criteria-non-matched | 2 |
| 212 | class-matched | 1 |
| 213 | iialpha-amplified | 1 |
| 214 | iii-controlled | 1 |
| 215 | aspirin-assigned | 1 |
| 216 | ii-defined | 2 |
| 217 | 3-refined | 1 |
| 218 | ii-typed | 1 |
| 219 | iii-based | 1 |
| 220 | dehydrogenase-bright-treated | 1 |
| 221 | i-associated | 3 |
| 222 | contrast-calculated | 1 |
| 223 | ii-targeted | 1 |
| 224 | individual-randomized | 2 |
| 225 | randomized/nonrandomized | 1 |
| 226 | ii-gold | 1 |
| 227 | 45-second | 1 |
| 228 | vhrd | 3 |
| 229 | cyanidiophyceae | 1 |
| 230 | caldilineae | 3 |
| 231 | na3ni2fe | 1 |
| 232 | a=large | 1 |
| 233 | ie/iie | 2 |
| 234 | medians-x-time | 2 |
| 235 | seco-casbane | 1 |
| 236 | fluoride-trifluoroethylene | 1 |
| 237 | approach.one | 1 |
| 238 | paleotemperature | 1 |
| 239 | aminoethylphosphonate | 1 |
| 240 | a-progressive | 1 |
| 241 | ii-prospective | 3 |
| 242 | prospective/retrospective | 4 |
| 243 | a-valve | 1 |
| 244 | i-binding | 1 |
| 245 | ii-expressing | 2 |
| 246 | iii-sandblasting | 1 |
| 247 | ii-detoxifying | 1 |
| 248 | sitong | 1 |
| 249 | rerg | 1 |
| 250 | i-h | 7 |
| 251 | i-outreach | 1 |
| 252 | 3-vmh | 1 |
| 253 | 3/machado-joseph | 1 |
| 254 | hrh | 2 |
| 255 | 0-i | 5 |
| 256 | iv-i | 1 |
| 257 | 0/i | 3 |
| 258 | i+ii | 14 |
| 259 | 0-ii | 5 |
| 260 | 5-ii | 4 |
| 261 | ia-ii | 1 |
| 262 | ib-ii | 1 |
| 263 | i-ii | 521 |
| 264 | ι-ii | 1 |
| 265 | ib/ii | 7 |
| 266 | ilate/ii | 2 |
| 267 | i/ii | 402 |
| 268 | iii | 16,262 |
| 269 | i+ii+iii | 1 |
| 270 | v+iii | 4 |
| 271 | 0-iii | 13 |
| 272 | ib-iii | 3 |
| 273 | iib/c-iii | 1 |
| 274 | i-iii | 281 |
| 275 | gradei-iii | 1 |
| 276 | ii-iii | 243 |
| 277 | i-ii-iii | 2 |
| 278 | iib/iii | 22 |
| 279 | ii/iii | 289 |
| 280 | ptnmiii | 1 |
| 281 | i-viii | 4 |
| 282 | iii-viii | 1 |
| 283 | i‒iii | 1 |
| 284 | ≤iii | 1 |
| 285 | ≥iii | 10 |
| 286 | ptnmii | 1 |
| 287 | iorii | 1 |
| 288 | ≤ii | 4 |
| 289 | ≥ii | 13 |
| 290 | ptnmi | 1 |
| 291 | indices-mepi | 1 |
| 292 | 3-vi | 4 |
| 293 | v/vi | 2 |
| 294 | iv/vi | 1 |
| 295 | ≥i | 1 |
| 296 | tock | 3 |
| 297 | ex-l | 4 |
| 298 | i/ii-cinderella-trial | 1 |
| 299 | ii-trial | 2 |
| 300 | marval | 2 |
| 301 | a-cll | 2 |
| 302 | ph+cml | 1 |
| 303 | 1-methoxy-2-propanol | 2 |
| 304 | angiotensin-system | 2 |
| 305 | attom | 2 |
| 306 | polyphenism | 1 |
| 307 | yun-xian | 1 |
| 308 | bev/ifn | 4 |
| 309 | i+prim-o-glucosylcimifugin | 1 |
| 310 | iiiβ-tubulin | 9 |
| 311 | hyperodapedon | 1 |
| 312 | 2/3/invasion | 1 |
| 313 | 1-hypertension | 2 |
| 314 | post-integration | 1 |
| 315 | recondition | 1 |
| 316 | self-resolution | 1 |
| 317 | pentron | 4 |
| 318 | b.o.o | 1 |
| 319 | t2-4nzero-1mzero | 1 |
| 320 | 0-p | 3 |
| 321 | +r | 1 |
| 322 | toscar | 2 |
| 323 | pounder | 1 |
| 324 | 3-greater | 1 |
| 325 | shifter | 2 |
| 326 | melter | 1 |
| 327 | 1.24-hour | 1 |
| 328 | 65-74yr | 1 |
| 329 | iv-acs | 2 |
| 330 | eccds | 2 |
| 331 | stonees | 2 |
| 332 | i/ii-studies | 2 |
| 333 | antiepileptics/barbiturates | 1 |
| 334 | wallemiomycetes | 1 |
| 335 | a-hsfs | 1 |
| 336 | 3/cis | 2 |
| 337 | rates.this | 1 |
| 338 | iii-trials | 1 |
| 339 | shifters | 1 |
| 340 | ends-products | 1 |
| 341 | 4t | 3 |
| 342 | 5t | 6 |
| 343 | iiibwet | 1 |
| 344 | 5/left | 1 |
| 345 | 8/left | 1 |
| 346 | colt | 2 |
| 347 | immmunoadsorbent | 1 |
| 348 | progesterone-dependent | 1 |
| 349 | preconcept | 2 |
| 350 | b-rt | 2 |
| 351 | vert | 3 |
| 352 | tmrt | 2 |
| 353 | 5-knockout | 1 |
| 354 | iii+v | 1 |
| 355 | ii-v | 15 |
| 356 | iii-v | 47 |
| 357 | iv-v | 35 |
| 358 | iv/v | 11 |
| 359 | iiib+iv | 2 |
| 360 | 0-iv | 2 |
| 361 | ib1-iv | 1 |
| 362 | iia-iv | 1 |
| 363 | iiia-iv | 1 |
| 364 | iib-iv | 17 |
| 365 | iiib-iv | 31 |
| 366 | ic-iv | 9 |
| 367 | iic-iv | 1 |
| 368 | iiic-iv | 2 |
| 369 | i-iv | 88 |
| 370 | ii-iv | 256 |
| 371 | iii-iv | 350 |
| 372 | ili-iv | 1 |
| 373 | v-iv | 1 |
| 374 | iiia/b/iv | 1 |
| 375 | iiib/iv | 91 |
| 376 | iiic/iv | 4 |
| 377 | i-ii/iv | 1 |
| 378 | iii/iv | 326 |
| 379 | i/ii/iii/iv | 7 |
| 380 | iv/iv | 4 |
| 381 | iii–iv | 1 |
| 382 | iv‒v | 1 |
| 383 | t3n0-1m0gx | 1 |
| 384 | iia-study | 1 |
| 385 | ii-cleopatra-study | 1 |
| 386 | iib-study | 1 |
| 387 | i-study | 1 |
| 388 | iiib/inflammatory | 1 |
| 389 | 2000~~ | 1 |
| 390 | eyetoy™ | 1 |
| 391 | ⅲ/ⅳ | 1 |